FR06C0024I2 - Anticorps humanises diriges contre la molecule d'adhesion leucocytaire vla-4 - Google Patents

Anticorps humanises diriges contre la molecule d'adhesion leucocytaire vla-4

Info

Publication number
FR06C0024I2
FR06C0024I2 FR06C0024C FR06C0024C FR06C0024I2 FR 06C0024 I2 FR06C0024 I2 FR 06C0024I2 FR 06C0024 C FR06C0024 C FR 06C0024C FR 06C0024 C FR06C0024 C FR 06C0024C FR 06C0024 I2 FR06C0024 I2 FR 06C0024I2
Authority
FR
France
Prior art keywords
directed against
humanized antibodies
antibodies directed
adhesion molecule
leukocyte adhesion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR06C0024C
Other languages
English (en)
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Athena Neurosciences Inc
Original Assignee
Athena Neurosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Athena Neurosciences Inc filed Critical Athena Neurosciences Inc
Publication of FR06C0024I1 publication Critical patent/FR06C0024I1/fr
Application granted granted Critical
Publication of FR06C0024I2 publication Critical patent/FR06C0024I2/fr
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FR06C0024C 1994-01-25 2006-07-27 Anticorps humanises diriges contre la molecule d'adhesion leucocytaire vla-4 Active FR06C0024I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18626994A 1994-01-25 1994-01-25
PCT/US1995/001219 WO1995019790A1 (en) 1994-01-25 1995-01-25 Humanized antibodies against leukocyte adhesion molecule vla-4

Publications (2)

Publication Number Publication Date
FR06C0024I1 FR06C0024I1 (cs) 2006-10-13
FR06C0024I2 true FR06C0024I2 (fr) 2009-01-02

Family

ID=22684288

Family Applications (1)

Application Number Title Priority Date Filing Date
FR06C0024C Active FR06C0024I2 (fr) 1994-01-25 2006-07-27 Anticorps humanises diriges contre la molecule d'adhesion leucocytaire vla-4

Country Status (21)

Country Link
EP (2) EP1759709B1 (cs)
JP (5) JP4115517B2 (cs)
KR (1) KR100367948B1 (cs)
CN (1) CN1211123C (cs)
AT (1) ATE333895T1 (cs)
AU (1) AU703152B2 (cs)
CA (1) CA2182013C (cs)
DE (2) DE122006000043I1 (cs)
DK (2) DK1759709T3 (cs)
ES (2) ES2424292T3 (cs)
FI (1) FI117509B (cs)
FR (1) FR06C0024I2 (cs)
HU (1) HU220799B1 (cs)
LU (1) LU91271I2 (cs)
MX (1) MX9602971A (cs)
NL (1) NL300238I2 (cs)
NO (3) NO319867B1 (cs)
NZ (1) NZ279730A (cs)
PL (1) PL181827B1 (cs)
PT (1) PT804237E (cs)
WO (1) WO1995019790A1 (cs)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6307025B1 (en) 1989-04-28 2001-10-23 Biogen, Inc. VCAM fusion proteins and DNA coding therefor
US5871734A (en) * 1992-01-13 1999-02-16 Biogen, Inc. Treatment for asthma with VLA-4 blocking agents
US5932214A (en) 1994-08-11 1999-08-03 Biogen, Inc. Treatment for inflammatory bowel disease with VLA-4 blockers
AU688751B2 (en) 1993-01-12 1998-03-19 Biogen Idec Ma Inc. Recombinant anti-VLA4 antibody molecules
DK0682529T4 (da) * 1993-02-09 2006-05-15 Biogen Idec Inc Antistof til behandling af insulinkrævende diabetes
US7435802B2 (en) 1994-01-25 2008-10-14 Elan Pharaceuticals, Inc. Humanized anti-VLA4 immunoglobulins
US5840299A (en) * 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
US7750137B2 (en) 1995-09-01 2010-07-06 Millennium Pharmaceuticals, Inc. Mucosal vascular addressins
US7803904B2 (en) 1995-09-01 2010-09-28 Millennium Pharmaceuticals, Inc. Mucosal vascular addressing and uses thereof
US6551593B1 (en) 1995-02-10 2003-04-22 Millennium Pharmaceuticals, Inc. Treatment of Inflammatory bowel disease by inhibiting binding and/or signalling through α 4 β 7 and its ligands and madcam
US7147851B1 (en) 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
WO1998051345A2 (en) * 1997-05-09 1998-11-19 The John P. Robarts Research Institute Method for dislodging infiltrated leukocytes from a tissue
DE19741235A1 (de) 1997-09-18 1999-03-25 Hoechst Marion Roussel De Gmbh Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE19741873A1 (de) * 1997-09-23 1999-03-25 Hoechst Marion Roussel De Gmbh Neue 5-Ring-Heterocyclen, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE19751251A1 (de) 1997-11-19 1999-05-20 Hoechst Marion Roussel De Gmbh Substituierte Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmezeutische Präparate
DE19821483A1 (de) 1998-05-14 1999-11-18 Hoechst Marion Roussel De Gmbh Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
US7618630B2 (en) 1998-09-14 2009-11-17 Board Of Regents, The University Of Texas System Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists
CZ302997B6 (cs) * 1998-09-14 2012-02-15 Board Of Regents, The University Of Texas System Použití protilátky nebo jejího fragmentu vázajícího antigen pro výrobu farmaceutického prípravku
EE05662B1 (et) * 1999-04-22 2013-06-17 Biogen, Inc. Fibroosi ravimise kompositsioon, mis kasutab integriin alfa-4 subhiku antagonisti ja selle kompositsiooni kasutamine
DE19922462A1 (de) 1999-05-17 2000-11-23 Aventis Pharma Gmbh Spiro-imidazolidinderivate, ihre Herstellung ihre Verwendung und sie enthaltende pharmazeutische Präparate
SI2314315T1 (sl) 1999-06-01 2015-04-30 Biogen Idec Ma Inc. Blokirno monoklonsko protitelo proti humani alfa1 i-domeni vla-1 in njegova uporaba za zdravljenje vnetnih obolenj
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
DE60043308D1 (de) * 1999-12-16 2009-12-24 Biogen Idec Inc Verfahren zur behandlung der schädigung des zentralnervensystems durch ischämie oder durch hämorrhagie mit antagonisten von alpha4 integrin
DE10111877A1 (de) 2001-03-10 2002-09-12 Aventis Pharma Gmbh Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
UA83791C2 (ru) 2001-04-13 2008-08-26 Байоджен Айдек Ма Инк. Антитело против vla-1, фармацевтическая композиция, которая его содержит, и из применение для лечения индивидуума с иммунологическим расстройством, опосредованным vla-1
DE10137595A1 (de) 2001-08-01 2003-02-13 Aventis Pharma Gmbh Neue Imidazolidinderivate, ihre Herstellung und ihre Verwendung
TWI346558B (en) 2002-02-25 2011-08-11 Elan Pharm Inc Pharmaceutical composition for chronic treatment of inflammation and use thereof
JP2005535572A (ja) * 2002-04-12 2005-11-24 メディミューン，インコーポレーテッド 組換え抗インターロイキン−９抗体
GB0210121D0 (en) 2002-05-02 2002-06-12 Celltech R&D Ltd Biological products
TWI323265B (en) * 2002-08-06 2010-04-11 Glaxo Group Ltd Antibodies
CN100432105C (zh) * 2002-12-17 2008-11-12 默克专利有限公司 与gd2结合的小鼠14.18抗体的人源化抗体(h14.18)以及其与il-2的融合
CU23403A1 (es) * 2003-04-23 2009-08-04 Centro Inmunologia Molecular Anticuerpos recombinantes y fragmentos que reconocen el gangliósido n-glicolil gm3 y su uso para diagnóstico y tratamiento de tumores
BRPI0418026A (pt) 2003-12-22 2007-04-17 Ajinomoto Kk derivados de fenilalanina ou sais farmaceuticamente aceitáveis destes, composição farmacêutica, antagonista de alfa4 integrina, e, agente terapêutico ou agente preventivo para doenças
US20090202527A1 (en) * 2004-11-19 2009-08-13 Biogen Idec Ma Inc. Treatment for multiple sclerosis
US20070122404A1 (en) * 2005-11-17 2007-05-31 O'keefe Theresa L Humanized immunoglobulin reactive with alpha4beta7 integrin
CA2652815C (en) 2006-05-25 2015-12-15 Biogen Idec Ma Inc. Methods of treating stroke
EP2124996A4 (en) 2007-02-20 2010-03-24 Merrimack Pharmaceuticals Inc METHOD FOR TREATING MULTIPLE SCLEROSIS BY ADMINISTERING AN ALPHA FETOPROTEIN COMBINED WITH AN INTEGRINANT AGONIST
AR067011A1 (es) * 2007-06-14 2009-09-30 Biogen Idec Inc Formulaciones de anticuerpos
KR101449521B1 (ko) 2007-12-13 2014-10-13 가부시끼가이샤 도꾸야마 포토크로믹 경화성 조성물 및 경화체
EA022201B1 (ru) 2008-04-11 2015-11-30 Мерримак Фармасьютикалз, Инк. Агент, способный связываться с опухолевой клеткой, содержащий линкер на основе hsa, и его применение
ES2751946T3 (es) 2009-03-20 2020-04-02 Amgen Inc Anticuerpo antagonista específico del heterodímero alfa-4-beta-7
WO2011020874A1 (en) 2009-08-20 2011-02-24 Inserm (Institut National De La Sante Et De La Recherche Medicale) Vla-4 as a biomarker for prognosis and target for therapy in duchenne muscular dystrophy
ES2805873T3 (es) 2010-04-16 2021-02-15 Biogen Ma Inc Anticuerpos anti-VLA-4
EP3311834A1 (en) 2011-05-02 2018-04-25 Millennium Pharmaceuticals, Inc. Formulation for anti-alpha4beta7 antibody
UA116189C2 (uk) 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
US10160808B2 (en) 2012-02-16 2018-12-25 Santarus, Inc. Anti-VLA1 (CD49A) antibody pharmaceutical compositions
WO2018002036A1 (en) 2016-06-28 2018-01-04 Zaklady Farmaceutyczne Polpharma Sa Recombinant production of monoclonal antibodies
US20190374639A1 (en) 2016-11-21 2019-12-12 Polpharma Biologics S.A. Aqueous pharmaceutical formulations
EP3583126B1 (en) * 2017-02-17 2025-08-27 Sanofi Multispecific binding molecules having specificity to dystroglycan and laminin-2
EP3635093A1 (en) 2017-06-08 2020-04-15 Polpharma Biologics S.A. Improved methods of cell culture
KR102848349B1 (ko) 2018-06-04 2025-08-21 바이오젠 엠에이 인코포레이티드 감소된 효과기 기능을 갖는 항-ｖｌａ-4 항체
EP4284947A1 (en) 2021-01-29 2023-12-06 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods of assessing the risk of developing progressive multifocal leukoencephalopathy in patients treated with vla-4 antagonists

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
IL162181A (en) * 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
IL113261A (en) * 1989-09-01 1996-10-16 Hutchinson Fred Cancer Res Inhibition by peptides of lymphocyte adherence to vascular endothelium utilizing an extracellular matrix receptor-ligand interaction and pharmaceutical compositions containing said peptides
DK0625912T3 (da) * 1992-02-12 1997-10-27 Biogen Inc Behandling af inflammatorisk tarmsygdom
AU688751B2 (en) * 1993-01-12 1998-03-19 Biogen Idec Ma Inc. Recombinant anti-VLA4 antibody molecules
AUPP647298A0 (en) 1998-10-13 1998-11-05 Keystone Retaining Wall Systems, Inc. Retaining wall block

Also Published As

Publication number Publication date
WO1995019790A1 (en) 1995-07-27
DE122006000043I1 (de) 2007-02-15
EP0804237A1 (en) 1997-11-05
DE69535133D1 (de) 2006-09-07
FI117509B (fi) 2006-11-15
FR06C0024I1 (cs) 2006-10-13
NO963097L (no) 1996-09-24
JPH09508272A (ja) 1997-08-26
HU9602019D0 (en) 1996-09-30
HUT75129A (en) 1997-04-28
DK1759709T3 (da) 2013-06-10
ES2424292T3 (es) 2013-09-30
ATE333895T1 (de) 2006-08-15
DE69535133T2 (de) 2008-08-21
DK0804237T3 (da) 2006-10-16
KR970700513A (ko) 1997-02-12
FI962958A0 (fi) 1996-07-24
CN1140413A (zh) 1997-01-15
NO2006008I2 (no) 2009-06-15
ES2270425T3 (es) 2007-04-01
PL181827B1 (pl) 2001-09-28
JP5487382B2 (ja) 2014-05-07
NO319867B1 (no) 2005-09-26
MX9602971A (es) 1998-01-31
CA2182013A1 (en) 1995-07-27
JP2013165718A (ja) 2013-08-29
NL300238I1 (cs) 2006-10-02
JP2006045237A (ja) 2006-02-16
EP0804237B8 (en) 2006-11-08
AU1696095A (en) 1995-08-08
EP0804237B1 (en) 2006-07-26
EP1759709A1 (en) 2007-03-07
EP0804237A4 (en) 2003-04-16
FI962958L (fi) 1996-09-24
CA2182013C (en) 2007-07-17
NO2017040I2 (no) 2018-08-28
NL300238I2 (nl) 2007-05-01
JP4115517B2 (ja) 2008-07-09
JP2009235078A (ja) 2009-10-15
HU220799B1 (hu) 2002-05-28
LU91271I2 (fr) 2006-10-02
NO2006008I1 (no) 2006-08-07
NO963097D0 (no) 1996-07-24
NO2017040I1 (no) 2017-08-01
KR100367948B1 (ko) 2003-07-12
CN1211123C (zh) 2005-07-20
EP1759709B1 (en) 2013-02-27
PL315634A1 (en) 1996-11-25
PT804237E (pt) 2006-10-31
AU703152B2 (en) 1999-03-18
NZ279730A (en) 1998-04-27
JP2013173738A (ja) 2013-09-05

Similar Documents

Publication Publication Date Title
FR06C0024I2 (fr) Anticorps humanises diriges contre la molecule d'adhesion leucocytaire vla-4
FR2735198B1 (fr) Piece d'accastillage de type manille-cosse
DK0739275T3 (da) Fastgørelsesorgan
EP0999205A4 (en) AMINOCYCLOALKAN CONNECTIONS
IT1277973B1 (it) Procedimento per l'assemblaggio di semilavorati per calze-mutanda
ITMI942358A0 (it) Peptidi ad attivita' antiinfiammatoria
NO970463D0 (no) Påföringsbånd for rörledning, uten "primer"
DE69828937D1 (de) Piece d' interposition
IT1313563B1 (it) Testina per l'applicazione di collante in zone prestabilite diprodotti in genere.
ITBO940208A0 (it) Pistola perfezionata per l'applicazione di collante
ITRM950066A0 (it) Procedimento per la produzione di poliammide con aumentata rigidita'.
FR2724251B3 (fr) Structure d'etiquetage
KR940027138U (ko) "t"형 관이음구
IT1290654B1 (it) Stazione per l'applicazione di collante su articoli.
ITMI942219A0 (it) "composti ad attivita' cardiovascolare"
IT242597Y1 (it) L'assorbiumidodeodorante
ITPS940012A0 (it) Giunto di unione, particolarmente indicato per assemblare complementi d'arredo
ITMI940717A0 (it) Composizioni farmaceutiche ad attivita' antitossica
UA1291S (uk) Штурмовий ніж-пістолет "касатка"
SE9403120L (sv) Overall "Easy"
UA27881C2 (uk) Мийно-дезінфекційний засіб "збруч-2"
UA680S (uk) Судно-службово-роз'їздне
ITCT940031A0 (it) "sbufi"
SE9402579L (sv) GB Karlssons märkband
IT234267Y1 (it) Disposizione d'imballaggio per frigoriferi